TTVR STRONG Under Coverage With Evidence Development (CED) Study
Recruiting
Observational Study
Tricuspid Regurgitation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 65 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 2,044 (estimated)
- Sponsor
- Edwards Lifesciences · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This Coverage with Evidence Development (CED) study measures the long-term health outcomes of patients with severe, symptomatic Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Replacement procedure using the EVOQUE system.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Medicare eligible patients who have received an EVOQUE device or are EVOQUE eligible and have at least severe Tricuspid Regurgitation
Exclusion Criteria:
Commercially insured patients who have received an EVOQUE device or are EVOQUE eligible or Medicare eligible patients with …
Contacts